| Acquired by | Biotie Therapies |
| Price | $122M |
| Date | 1/11 |
| Website | synosia.com |
| Category | BioTech |
| julie.walters@tud... | |
| Employees | |
| Description | Pharmaceutical Compounds |
| TOTAL | $91.5M |
| FUNDING TOTAL | $91.5M |
| Venture Round, 1/07 Versant Ventures Abingworth 5AM Ventures Novo A/S | $32.5M |
| Series B, 1/09 Aravis Ventures Investor Growth Capital Swiss Helvetia Fund Versant Ventures Abingworth Novo Ventures 5AM Ventures | $29M |
| Series C, 10/10 UCB Pharma Versant Ventures 5AM Ventures Novo A/S Aravis Ventures Investor Growth Capital Swiss Helvetia Fund | $30M |
Synosia Therapeutics develops and intends to commercialise products for unmet medical needs in psychiatry and neurology. The privately-owned company has in its pipeline six clinical-stage compounds acquired through partnerships with Novartis, Roche and Syngenta. Two of the compounds are marketed drugs being tested in new indications to extend their reach into neurological and psychiatric diseases with high unmet medical need, including anxiety and Parkinson’s disease.
